Stock SRPT SAREPTA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Real-time Estimate Cboe BZX
Other stock markets
 10:20:41 2024-05-01 am EDT 		5-day change 1st Jan Change
128.2 USD +1.18% Intraday chart for Sarepta Therapeutics, Inc. +2.59% +32.18%
Mar. 21 FDA greenlights Italfarmaco's drug for rare muscular dystrophy RE
Mar. 12 Transcript : Sarepta Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03:05 PM

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
BU
REGENXBIO And Sarepta Agree To Stay Litigation Pending Outcome Of Sarepta's IPR Petition
AQ
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - March 29, 2024
AQ
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Sarepta Therapeutics Announces Call for Applications for the 2024 LGMD Grant Award Program
AQ
Sarepta Therapeutics to Present at Upcoming Investor Conferences
BU
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
BU
Sarepta Therapeutics: Q4 Earnings Snapshot
AQ
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
BU
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
BU
Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
BU
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
BU
Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
BU
District Court Grants Summary Judgment And Invalidates Patent In REGENXBIO v. Sarepta Litigation
AQ
U.S. District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV Technology Patent Infringement Lawsuit
AQ
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SRPT Stock
  4. News Sarepta Therapeutics, Inc.
  5. Press Releases